Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818368 | 1.00 | HRH4 (0.54) | HRH4HRH3PDE10AMAP4K4PIM1 | |
| SCHEMBL4132593 | 0.84 | HRH4 (0.46) | HRH4HRH3PDE10AMAP4K4PIM1 | |
| SCHEMBL4132590 | 0.84 | HRH4 (0.46) | HRH4HRH3PDE10AMAP4K4PIM1 | |
| SCHEMBL2166160 | 0.80 | HRH4 (0.70) | HRH4HRH3PDE10AMAP4K4CKS1B | |
| SCHEMBL605597 | 0.78 | HRH3 (0.74) | HRH4HRH3 | |
| SCHEMBL605598 | 0.78 | HRH3 (0.74) | HRH4HRH3 | |
| SCHEMBL604874 | 0.71 | HRH4 (0.56) | HRH4HRH3 | |
| SCHEMBL3816114 | 0.71 | HRH3 (0.57) | HRH4HRH3PDE10A | |
| SCHEMBL3816118 | 0.71 | HRH3 (0.57) | HRH4HRH3PDE10A | |
| SCHEMBL604869 | 0.71 | HRH4 (1.00) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278313-B2 | Macrocyclic spiro pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | DPYD, TYMS, TYMP | HRH4 4235/4885HRH3 4454/4885PDE10A 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.